
    
      This is a phase I, single center, randomized, double-blind and parallel group clinical trial.

      The primary objective is to assess the pharmacokinetic similarity of single and subcutaneous
      injections of MW032 and Xgeva® in healthy volunteers.

      The secondary objective are to assess the Clinical safety and immunogenicity similarity of
      single and subcutaneous injections of MW032 and Xgeva® in healthy volunteers.

      At the same time, preliminary evaluate the pharmacodynamic similarity between MW032 and
      Xgeva®.

      Subjects would receive a single 120mg（1.7mL）of MW032 or Xgeva® through subcutaneous
      injection.
    
  